Eli Lilly: A Biotech Powerhouse
Eli Lilly (NYSE: LLY) has embarked on a journey fueled by innovation in the biotech realm, harnessing the potential of GLP-1s and artificial intelligence (AI). Collaborating with industry giants like OpenAI, the company dives into AI-driven drug discovery, a realm brimming with promise and speed. An impactful recent win for Eli Lilly came through its GLP-1 drug, Mounjaro, which outperformed Novo Nordisk’s Ozempic in weight loss. With each endeavor turning to gold, the pricey yet valuable LLY stock positions itself as a contender eyeing the trillion-dollar market cap milestone.
Dell Technologies: Surging Ahead with AI Solutions
Among the new entrants vying for Magnificent 7 status is Dell Technologies (NYSE: DELL), riding a remarkable 95% stock surge this year. Identified as a thriving AI player, Dell’s AI servers present a compelling case in a landscape overshadowed by GPU behemoths. At a modest 18.7 forward price-to-earnings ratio, DELL stock emerges as a beacon of value, attracting accolades from leading analysts like Morgan Stanley’s Erik Woodring. As AI server demand soars, concerns over server margins may fall short in capturing Dell’s full potential.
Netflix: Streaming to the Pinnacle
Netflix (NASDAQ: NFLX) may not fit the stereotypical AI star narrative, but its continuous stream of enticing content has kept the platform afloat while rivals falter. As subscription costs rise marginally, consumers remain content with the value Netflix delivers. Co-CEO Greg Peters emphasizes that price hikes fuel a richer content library, a strategy that bolsters Netflix’s pricing power. Satisfying audiences with binge-worthy shows positions NFLX as a contender for the coveted Magnificent 7 status.